摘要
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic disorders related to hematopoietic stem and progenitor cell dysfunction. However, therapies that are currently used to target hematopoietic stem cells are not effective. These therapies are able to slow the evolution toward acute myeloid leukemia but cannot eradicate the disease. Mesenchymal stem cells (MSCs) have been identified as one of the main cellular components of the bone marrow microenvironment, which plays an indispensable role in normal hematopoiesis. When functional and regenerative capacities of aging MSCs are diminished, some enter replicative senescence, which promotes inflammation and disease progression. Recent studies that investigated the contribution of bone marrow microenvironment and MSCs to the initiation and progression of the disease have offered new insights into the MDS. This review presents the latest updates on the role of MSCs in the MDS and discusses potential targets for the treatment of MDS.
学科与关键词
- Mesenchymal Stem Cell Senescence and Rejuvenation: Current Status and ChallengesZhou, Xueke; Hong, Yimei; Zhang, Hao; Li, Xin*Frontiers in Cell and Developmental Biology, 2020, 8: 364.被引 68
- Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic HematopoiesisMasters of Survival and Clonality?Pleyer Lisa; Valent Peter; Greil RichardInternational Journal of Molecular Sciences, 2016, 17(7): 1009.
- Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β-catenin signalling by parallel RNA sequencing and dysfunctional phenotypesXu, Ruohao; Huang, Xin; Li, Chao; Deng, Chengxin; Li, Minming; Wu, Ping; Geng, Suxia; Lai, Peilong; Lu, Zesheng; Weng, Jianyu*; Du, Xin*British Journal of Haematology, 2021, 193(5): 928-940.被引 4
